Blackstone to buy life sciences investment firm Clarus
Blackstone said Oct. 4 that it agreed to buy Clarus. Financial terms weren’t announced. Clarus with offices in Boston and San Francisco, is a life sciences investment firm that has raised $2.6 billion since its founding. The deal will launch Blackstone Life Sciences, a platform that will invest across the life-cycle of companies and products within the key life sciences sectors. Nick Galakatos, PhD, who co-founded Clarus in 2005 and is a managing director, will become head of Blackstone Life Sciences.
4 October 2018•4 mins read
